Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors.

被引：0
作者：
Li, Jian
Xu, Ye
Zang, Aimin
Gao, Yunong
Gao, Quanli
Zhang, Yanqiao
Wang, Dong
Xu, Jianming
Yuan, Ying
Jiang, Haiping
Ying, Jieer
Shi, Chunmei
Deng, Yanhong
Wang, Jing
Liu, Tianshu
Huang, Yi
Xu, Yaling
Wang, Yidi
Fei, Cong
Shen, Lin
机构：
[1] Beijing Canc Hosp, Beijing, Peoples R China
[2] Fudan Univ Shanghai, Canc Ctr, Shanghai, Peoples R China
[3] Hebei Univ, Affiliated Hosp, Hebei, Peoples R China
[4] Henan Canc Hosp, Zhengzhou, Henan, Peoples R China
[5] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
[6] Chongqing Univ, Canc Hosp, Chongqing, Peoples R China
[7] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing, Peoples R China
[8] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Zhejiang, Peoples R China
[9] Med Sch Zhejiang Univ, Affiliated Hosp 1, Zhejiang, Peoples R China
[10] Zhejiang Canc Hosp, Beijing, Peoples R China
[11] Fujian Med Univ, Union Hop, Fujian, Peoples R China
[12] Sun Yat Sen Univ, Affiliated Hosp 6, Guangzhou, Peoples R China
[13] Hunan Canc Hosp, Changsha, Hunan, Peoples R China
[14] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
[15] Hubei Canc Hosp, Wuhan, Hubei, Peoples R China
[16] BeiGene Co Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14556
引用
收藏
页数：1
相关论文
共 50 条
[31]   FREQUENCY OF AND TESTING PATTERNS FOR MICROSATELLITE INSTABILITY HIGH (MSI-H) AND DEFICIENT MISMATCH REPAIR (DMMR) AMONG SOLID TUMORS IN A US COMMUNITY ONCOLOGY SETTING [J].
Chase, M. ;
Vasudevan, A. ;
Amonkar, M. ;
Myer, N. ;
Wang, T. ;
Prabhu, V ;
Turzhitsky, V ;
Spira, A. .
VALUE IN HEALTH, 2022, 25 (07) :S452-S452
[32]   Nivolumab plus ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142. [J].
Andre, Thierry ;
Lonardi, Sara ;
Wong, Mark ;
Lenz, Heinz-Josef ;
Gelsomino, Fabio ;
Aglietta, Massimo ;
Morse, Michael ;
Van Cutsem, Eric ;
McDermott, Raymond S. ;
Hill, Andrew G. ;
Sawyer, Michael B. ;
Hendlisz, Alain ;
Neyns, Bart ;
Svrcek, Magali ;
Moss, Rebecca Anne ;
Ledeine, Jean-Marie ;
Cao, Z. Alexander ;
Kamble, Shital ;
Kopetz, Scott ;
Overman, Michael J. .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[33]   Dostarlimab in advanced/recurrent (A/R) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study [J].
Oaknin, Ana ;
Pothuri, Bhavana ;
Gilbert, Lucy ;
Sabatier, Renaud ;
Ghamande, Sharad ;
Gravina, Adriano ;
Calvo, Emiliano ;
Banerjee, Susana ;
Mangan, Niamh ;
Miller, Rowan E. ;
Pikiel, Joanna ;
Mirza, Mansoor R. ;
Duan, Tao ;
Zildjian, Sybil ;
Zografos, Eleftherios ;
Veneris, Jennifer ;
Tinker, Anna V. .
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 :133-134
[34]   Neoadjuvant nivolumab plus ipilimumab in microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) rectal tumors: ECOG-ACRIN EA2201 [J].
Ciombor, K. K. ;
Hong, S. ;
Eng, C. ;
Yao, X. ;
You, N. ;
Das, P. ;
Chakravarthy, A. ;
O'Dwyer, P. J. .
ANNALS OF ONCOLOGY, 2024, 35 :S104-S104
[35]   PATIENT-REPORTED OUTCOMES (PROS) IN THE GARNET TRIAL IN PATIENTS (PTS) WITH ADVANCED OR RECURRENT MISMATCH REPAIR DEFICIENT/MICROSATELITE INSTABILITY-HIGH (DMMR/MSI-H) ENDOMETRIAL CANCER (EC) TREATED WITH DOSTARLIMAB [J].
Kristeleit, Rebecca ;
Mathews, Cara ;
Redondo, Andres ;
Huang, Joice ;
Eliason, Laurie ;
Im, Ellie ;
Brown, Jubilee .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 :A40-A41
[36]   Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164 [J].
Le, Dung T. ;
Diaz Jr, Luis A. ;
Kim, Tae Won ;
Van Cutsem, Eric ;
Geva, Ravit ;
Jaeger, Dirk ;
Hara, Hiroki ;
Burge, Matthew ;
O'Neil, Bert H. ;
Kavan, Petr ;
Yoshino, Takayuki ;
Guimbaud, Rosine ;
Taniguchi, Hiroya ;
Elez, Elena ;
Al-Batran, Salah-Eddin ;
Boland, Patrick M. ;
Cui, Yi ;
Leconte, Pierre ;
Marinello, Patricia ;
Andre, Thierry .
EUROPEAN JOURNAL OF CANCER, 2023, 186 :185-195
[37]   Patient-reported outcomes (PROs) in the GARNET trial in patients (pts) with advanced or recurrent mismatch repair deficient/microsatelite instability-high (dMMR/MSI-H) endometrial cancer (EC) treated with dostarlimab [J].
Kristeleit, R. ;
Matthews, C. ;
Redondo, A. ;
Huang, J. ;
Eliason, L. ;
Im, E. ;
Brown, J. .
ANNALS OF ONCOLOGY, 2020, 31 :S637-S637
[38]   A phase III study of nivolumab (NIVO), NIVO plus ipilimumab (IPI), or chemotherapy (CT) for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Checkmate 8HW [J].
Abdullaev, Sandzhar ;
Andre, Thierry ;
Lei, Ming ;
Lenz, Heinz-Josef ;
Novotny, James ;
Paulson, Andrew Scott ;
Tejpar, Sabine ;
Yamazaki, Kentaro ;
Ledeine, Jean-Marie .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[39]   Systematic literature review (SLR) of prognostic factors (PFs) in locally advanced rectal cancer (LARC) and mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) rectal cancer (RC). [J].
Capdevila, Jaume ;
O'Donnell, Sean ;
Borkowska, Katarzyna ;
Frampton, James ;
Betts, Marissa ;
Maierhofer, Courtney ;
Kalilani, Linda ;
Garside, Jamie ;
Wang, Huifen .
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) :303-303
[40]   Clinical efficacy and biomarker analysis of pucotenlimab (HX008) in patients with previously treated advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A single-arm, multicenter, phase 2 study. [J].
Zhang, Bo ;
Song, Yan ;
Luo, Suxia ;
Yin, Xianli ;
Li, Enxiao ;
Wang, Hui ;
He, Yifu ;
Liu, Zhihui ;
Fan, Qingxia ;
Liang, Xinjun ;
Shu, Yongqian ;
Liu, Yunpeng ;
Xu, Nong ;
Zhang, Shu ;
Zhuang, Zhixiang ;
Zhang, Jingdong ;
Kou, Xiaoge ;
Wang, Fen ;
Zhu, Xiaodong ;
Huang, Jing .
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 :799-799
12345